Tender Offer / Target company: Pharma SGP Holding SE; Bidder: Futrue GmbH

EQS-WpÜG: Futrue GmbH / Tender Offer Tender Offer / Target company: Pharma SGP Holding SE; Bidder: Futrue GmbH 10.06.2025 / 08:35 CET/CEST Dissemination of an announcement according to the German Securities Acquisition and Takeover Act (WpÜG), transmitted by EQS News - a service of EQS Group. The bidder is solely responsible for the content of this announcement. BIDDER SECTION 10 WPÜG ANNOUNCEMENT

– Convenience Translation –

(Only the German version is legally binding)

 

THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT INTENDED FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY COUNTRY WHERE SUCH PUBLICATION, DISTRIBUTION OR TRANSMISSION WOULD BE VIOLATING THE RELEVANT LEGAL PROVISIONS OF SUCH COUNTRY.

Publication of the decision to make a public delisting tender offer (öffentliches Delisting-Erwerbsangebot) pursuant to Section 10 paras. 1 and 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz – WpÜG) in conjunction with Section 39 para. 2 sent. 3 no. 1 of the German Stock Exchange Act (Börsengesetz – BörsG)

 

Bidder:

FUTRUE GmbH
Am Haag 14
82166 Gräfelfing
Germany

registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Munich under HRB 173092

Target:

PharmaSGP Holding SE
Lochhamer Schlag 1
82166 Gräfelfing
Germany

registered with the commercial register (Handelsregister) of the local court (Amtsgericht) of Munich under HRB 255684

ISIN: DE000A2P4LJ5
WKN: A2P4LJ

Today, FUTRUE GmbH (the “Bidder”) decided to make a public delisting tender offer (öffentliches Delisting-Erwerbsangebot) to the shareholders of PharmaSGP Holding SE (“PharmaSGP”) for the acquisition of all no-par value bearer shares (auf den Inhaber lautende Stückaktien) in PharmaSGP (ISIN DE000A2P4LJ5), each share representing a proportionate amount of EUR 1.00 of the share capital of PharmaSGP (each a “PharmaSGP Share”), which are not directly held by the Bidder, against payment of a cash consideration of EUR 28.00 per PharmaSGP Share (the “Delisting Offer”). The offer price for the Delisting Offer will thus exceed the volume-weighted average share price of the PharmaSGP Shares during the last six months prior to today. The Delisting Offer will not be subject to any closing conditions.